D3-Selective Dopamine Agonist Platform: Eliminating D2-Mediated Side Effects in Parkinson’s and Movement Disorders
Every major dopaminergic therapy on the market today shares the same fundamental limitation: it cannot distinguish between two closely related receptor subtypes (D2 and D3). This technology changes that.